Ichnos Glenmark Innovation (IGI), a global clinical-stage biotechnology company focused on developing Multispecific™ antibodies in oncology, today announced a new development candidate, ISB 2301, a first-in-class, multispecific immune cells (T and NK) activator, for the potential treatment of multiple solid tumor indications. ISB 2301 targets three tumor-associated antigens to trigger tumor cell death and engages both T cells and NK cells to ignite the immune system.
“We engineered ISB 2301 to match the biological complexity of solid tumors in a way that conventional immunotherapies have not been able to address,” said Lida Pacaud, M.D., President and Chief Executive Officer (CEO). “By simultaneously targeting three tumor-associated antigens and engaging both T cells and NK cells, it deploys a level of multi-mechanistic precision that we believe sets a new benchmark for what multispecific antibodies can achieve in solid tumors.”
